Merck & Co. Inc., known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has granted approval for WELIREG® (belzutifan). This marks a significant development as WELIREG becomes the only approved treatment in the United States for adult and pediatric patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). These are rare tumors that originate from the same tissue, but differ in their location of formation. The approval is based on data from the LITESPARK-015 clinical trial, highlighting Merck's commitment to providing innovative therapies for patients with rare diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.